Photo by jonathanborba from unsplash
Pancreatoduodenectomy (PD) remains the only curative‐intent treatment option for patients with cancer affecting the head of the pancreas. It is high‐risk and overall morbidity is around 40%. Due to the… Click to show full abstract
Pancreatoduodenectomy (PD) remains the only curative‐intent treatment option for patients with cancer affecting the head of the pancreas. It is high‐risk and overall morbidity is around 40%. Due to the necessary resection and subsequent anastomoses required, multiple procedure‐specific complications are possible. An in‐depth understanding of the recent evidence on these will guide the consenting process and allow surgeons to evaluate their own performance.
Keywords:
pancreatoduodenectomy;
morbidity pancreatoduodenectomy;
procedure specific;
risk;
specific morbidity
Journal Title: ANZ Journal of Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ANZ Journal of Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!